Skip to main content
. Author manuscript; available in PMC: 2010 May 3.
Published in final edited form as: Exp Dermatol. 2009 Jun;18(6):548–552. doi: 10.1111/j.1600-0625.2008.00827.x

Table 3.

Analysis of the Portuguese and Spanish cohort consisting of PTC cases only.

Tumors BRAF mutant or wild-type BRAF mutant
Cases Controls OR (95%
CI)		 Cases Controls OR (95% CI)
MC1R
consensus		 41 40 reference 21 22 reference
1 MC1R
variant		 26 26 0.976
(0.486 to
1.958)		 8 8 1.048
(0.3324 to
3.302)
≥ 2 MC1R
variants		 7 8 0.854
(0.283 to
2.575)		 3 2 1.571
(0.2382 to
10.3653)
total 74 74 p = 0.961* 32 32 p = 0.894*

Given are odds ratios for any BRAF mutation status and for BRAF mutant cases only, depending on the number of MC1R variants compared to the matched control cohort.

*

Pearson chi-square test.